You track your sleep stages the way you track your splits and your lifts. So when deep-sleep minutes drift in the first weeks of a new testosterone protocol, you notice — and you want to know whether it's signal or noise.
This article is educational and not medical advice. It's written for the person who reads the raw data, not the summary card — and who wants to understand the mechanism well enough to ask a sharper question at the next visit.
Sleep architecture, briefly and precisely
A night of sleep cycles through stages: light sleep (N1, N2), slow-wave or "deep" sleep (N3), and REM. Deep sleep is where much of the body's overnight physical restoration is concentrated, and it's the stage most wearables try to estimate — imperfectly — from heart rate, movement, and heart-rate variability. Consumer devices don't measure brain waves; they infer stages, so treat any single night's number as an estimate with real error bars.
What matters biologically is that sleep and the male endocrine system are tightly coupled. Testosterone in men follows a circadian rhythm, rising through sleep and peaking in the early morning, and that rise is closely tied to sleep itself. In a controlled study, restricting healthy young men to five hours of sleep for one week lowered daytime testosterone [1]. The relationship runs both directions: sleep shapes hormones, and hormones shape sleep.
Source: [1] Effect of 1 Week of Sleep Restriction on Testosterone Levels in Young Healthy Men (JAMA), [2] FDA Testosterone Cypionate (DEPO-Testosterone) Prescribing Information (Warnings/Sleep Apnea)
Why the first months can look different in the data
Starting testosterone therapy introduces a new variable into a system your body has calibrated over decades. Several things can plausibly move sleep metrics early on, and it helps to separate them.
Rhythm and timing. Because endogenous testosterone normally rises during sleep, adding exogenous testosterone changes the daily hormonal pattern. Your body's feedback loops — the hypothalamic-pituitary-gonadal axis — adjust to the new input. During any adjustment period, the architecture of a night's sleep can shift before it settles.
Breathing during sleep. This is the well-documented safety consideration and the reason it deserves its own paragraph. The FDA-approved labeling for testosterone products notes that testosterone therapy may cause or worsen obstructive sleep apnea (OSA), particularly in those with risk factors such as obesity or chronic lung disease [2]. OSA fragments sleep and suppresses deep sleep, and it can show up on a wearable as more awakenings, a lower resting HRV, or an elevated overnight heart rate. This is distinct from a benign adjustment — it's a pattern worth flagging.
Downstream biomarkers. Testosterone therapy can raise hematocrit (the proportion of red blood cells), which is monitored precisely because higher values carry their own risks [3]. Metabolic and body-composition changes over months can also indirectly influence how you sleep. None of these are reasons to panic at a single noisy night; they're reasons the provider watches labs on a schedule.
Reading your wearable without over-reading it
An optimizer's failure mode is treating estimated data as ground truth. A few principles keep the analysis honest:
- Trend over nights, not single nights. Look at rolling 7- and 14-day averages of deep-sleep minutes, resting heart rate, and HRV rather than reacting to one bad reading.
- Control the confounders you already know. Late training, alcohol, evening carbohydrate timing, travel, and ambient temperature all move deep-sleep estimates independently of any hormone. A protocol change is easier to interpret when the rest of the inputs are stable.
- Watch the cluster, not the number. A meaningful signal is usually several metrics moving together — deep sleep down *and* resting heart rate up *and* HRV down *and* more awakenings — sustained across a couple of weeks.
The point of tracking isn't to self-diagnose. It's to arrive at your provider conversation with a clean, patterned data set instead of an anecdote.
When a deep-sleep shift is worth a conversation
Most early variability is exactly that — variability. The signals that genuinely warrant a message to your provider tend to be persistent and clustered:
- A sustained drop in deep sleep over one to two weeks that doesn't track with an obvious behavioral cause.
- New or worsening loud snoring, witnessed pauses in breathing, gasping, or waking unrefreshed despite adequate time in bed — the classic OSA picture the label flags [2].
- Morning headaches, unusual daytime sleepiness, or a rising resting heart rate alongside the sleep change.
- Any of the above paired with a scheduled lab that's trending — for example, a climbing hematocrit [3].
A responsive provider treats these as inputs to a protocol conversation, not as a verdict. That may mean ordering or reviewing sleep-focused evaluation, checking labs sooner, or adjusting an approach. What it should never mean is waiting a year to look at it.
Source: [3] Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline
The estrogen piece optimizers ask about
If you're thinking about the full picture, estradiol belongs in the conversation. In men, a portion of testosterone is converted to estradiol via the aromatase enzyme, and estradiol has its own physiological roles [4]. There is published work exploring associations between sex hormones — including estradiol — and sleep in men, though the literature is still developing and correlational in many places [5]. The practical takeaway isn't a target number to chase on your own; it's that a physician managing testosterone in isolation is managing half the system. How estradiol is monitored and interpreted is a clinical judgment made with your labs and your goals in front of the provider.
What good monitoring looks like
Major clinical guidance frames testosterone therapy as something that requires structured follow-up: baseline evaluation, confirmation of low testosterone on more than one morning measurement before starting, and periodic reassessment of symptoms, testosterone levels, hematocrit, and other markers on a defined schedule [3][6]. Your wearable data is a useful adjunct to that structure — a continuous stream between formal touchpoints — not a replacement for it. The optimizer's advantage is bringing both to the table.
Source: [3] Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline, [6] NIH MedlinePlus: Testosterone Levels and Aging
Where Velri fits
Velri is a technology and coordination company; it does not provide medical care. Velri can help coordinate lab work, connect you with an independent, licensed provider group for an evaluation, and — if a provider determines it's appropriate and writes a prescription — coordinate fulfillment through an independent, licensed pharmacy. Whether therapy is appropriate, and any monitoring plan, is decided solely by the independent provider; a prescription is never guaranteed.
Where a compounded medication is involved: compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state.
This article is educational and is not medical advice, diagnosis, or a recommendation to take any specific medication. Bring your questions — and your data — to a licensed provider.
